Shenzhen Hepalink Pharmaceutical Group’s subsidiary OncoVent has entered into a licence and distribution agreement with Orient EuroPharma (OEP) for the immunotherapeutic drug candidate, oregovomab.
Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.
Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries.
Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.
German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio.
Danaher, a science and technology company, has agreed to acquire biotech firm Aldevron from EQT Private Equity for an enterprise value of $9.bn.
Merck has completed the spinoff of Organon, which has now launched as new women’s health company.
Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile being positive.
Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.